I have the expertise in performing molecular epidemiology studies of cancer in the last 20 years. I was trained as a molecular epidemiologist, with an emphasis on genetic susceptibility to cancer in etiological research and clinical outcomes in translational studies. I have a broad background in epidemiology, with specific training and expertise in developing biomarkers and applying them to molecular epidemiology studies of cancer. My recent research largely focuses on genome-wide association studies and re-analysis of GWAS datasets, in which we are applying novel methods and statistical approaches to identify additional genetic variants that are predictors of risk and clinical outcomes for melanoma, lung cancer, prostate and breast cancer. The pathway analyses of genetic variants target those biological processes that are responsible for DNA repair and apoptosis, cell growth and signaling. I have a track record of publications, successful career development and previous experiences in grant management.